August 1, 2017 10:02 AM EDT
News Briefing

Lex­i­con grabs co-pro­mo op­tion on di­a­betes drug; Shkre­li ju­ry en­ters sec­ond day of de­lib­er­a­tions

Shehla Shakoor

Managing Director

→ Lex­i­con Phar­ma­ceu­ti­cals $LXRX is tak­ing a co-pro­mo­tion op­tion on its SGLT 1 / 2 drug so­tagliflozin for type 1 di­a­betes. Lex­i­con plans to mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times